Disease Domain | Count |
---|---|
Infectious Diseases | 7 |
Immune System Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 5 |
DNA vaccine | 5 |
Small molecule drug | 2 |
Therapeutic vaccine | 1 |
mRNA vaccine | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein | 2 |
Taste 2 receptors | 1 |
HCV NS4A x HCV NS4B x NS3 x NS5A | 1 |
NF-κB x p38 MAPK | 1 |
Mechanism HCV NS4A inhibitors [+3] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Taste 2 receptors agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2023 |
Sponsor / Collaborator |
Start Date23 May 2022 |
Sponsor / Collaborator |
Start Date01 Nov 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GLS-5310 ( SARS-CoV-2 S protein ) | COVID-19 More | Phase 2 Clinical |
INO-8000 ( HCV NS4A x HCV NS4B x NS3 x NS5A ) | Hepatitis C More | Phase 2 |
GLS-1200 ( Taste 2 receptors ) | Rhinitis, Allergic More | Phase 2 |
Zenuzolac ( NF-κB x p38 MAPK ) | COVID-19 More | Phase 2 |
VGX-3400 | Influenza in Birds More | Phase 1 |